Clinical trial · Observational
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
Retrospective Study of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Chemotherapy Agents
NCT07785180CI-TRIAL-00123728recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Blastic Plasmacytoid Dendritic Cell Neoplasm | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Chemotherapy
- description
- Adult participants with BPDCN who have been treated with chemotherapy regimens (at a minimum) as first-line treatment from May 2016.
- interventionNames
- Drug: Chemotherapy
Primary outcomes (9)
- measure
- Objective Response Rate
- timeFrame
- Baseline through Month 18
- measure
- Composite Complete Response
- timeFrame
- Baseline through Month 18
- measure
- Number of Participants Bridged to Stem Cell Transplant
- timeFrame
- Baseline through Month 18
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016 * Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123 * Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation Exclusion Criteria: * Participant has received an investigational agent as first-line therapy for BPDCN * Participant has received first-line therapy for BPDCN in an interventional clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.